Takeda Announces Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel® (darvadstrocel) in Complex Crohn s Perianal Fistulas - Iberonews iberonews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from iberonews.com Daily Mail and Mail on Sunday newspapers.
18.02.2022 - Takeda (TSE:4502/NYSE:TAK) today announced the first six-month interim analysis results from INSPIRE, in which clinical remission was observed in 65% of patients in both cohorts who were evaluated at 6 months.1 INSPIRE is a European, observational, .